Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension

Ali Ataya a,*, Angelina Somoracki b, Jessica Cope c, Hassan Alnuaima a

a Pulmonary Vascular Disease Program, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USA
b Department of Internal Medicine, University of Florida, Gainesville, FL, USA
c Department of Pharmacy, University of Florida, Gainesville, FL, USA

A R T I C L E   I N F O
Article history:
Received 12 January 2016
Received in revised form
1 June 2016
Accepted 22 July 2016
Available online 25 July 2016

Keywords:
Pulmonary hypertension
Pulmonary arterial hypertension
Transition
Parenteral
Inhaled
Prostacyclin

A B S T R A C T

Background: Parenteral prostacyclin therapy for PAH has allowed for improvements in functional status, quality of life and mortality. Parenteral therapies however carry an increased risk of line-associated complications. Inhaled prostacyclins are an attractive alternative therapy; however, limited data exists supporting the safety and outcomes after transition.

Methods: We describe a retrospective observational analysis of adults with PAH who were transitioned from a parenteral prostacyclin to inhaled treprostinil at our institution. Endpoints include duration of transition, hospital length of stay, adverse effects during transition, and cardiopulmonary function post transition.

Results: Eight patients were included, all of which were on triple therapy. Seven patients receiving intravenous prostacyclin therapy were transitioned in an ICU setting, while one patient was transitioned from subcutaneous treprostinil as an outpatient. The average ICU and hospital length of stay was 4.1 ± 0.7 days. Patient preference was the most common reason for transition (n = 5), followed by line complication (n = 2), and intolerance to parenteral therapy (n = 1). One adverse event was observed while initiating inhaled treprostinil that only required slowing of the transition process. On follow-up (19.6 ± 11.1 months) functional class did not change, and non-parametric test showed no change in 6MWD after transition (p = 0.62). One patient failed inhaled therapy necessitating transition back to intravenous therapy.

Conclusion: Transitioning patients from parenteral to inhaled prostacyclin therapy can be safely accomplished in specialized centers over a 48–72 h period. Patient preference was overwhelming the most prevalent reason for transition.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Pulmonary arterial hypertension (PAH) consists of a group of diseases affecting the pulmonary arterioles contributing to a pathological increase in the pulmonary arterial pressures and pulmonary vascular resistance, in the setting of a normal pulmonary artery occlusion pressure [1]. These hemodynamic changes, in turn, increase the load on the right ventricle leading to elevated right ventricle pressure and right-sided heart failure [2]. The advent of intravenous prostanoid therapies in the mid 1990s for the treatment of World Health Organization (WHO) Group I PAH has changed the management of this debilitating disease, with patients experiencing significant improvements in their functional status, cardiopulmonary function, quality of life, and mortality [3,4].

Long-term parenteral therapy, although life-saving, is cumbersome for patients and carries an increased risk of complications associated with the mode of administration, including line-associated thrombosis, infections, injection site pain, and inflammation [5–7]. Secondary to the short half-life of the parental prostanoids, abrupt therapy disruption due to one of the aforementioned complications can precipitate acute pulmonary hypertension [8]. Inhaled treprostinil (Tyvaso®), which received Food and Drug Administration approval in 2002, is an attractive alternative for many patients as its administered four times daily approximately four hours apart via the Tyvaso Inhalational System® [9]. Dosing is initiated at three breaths four times daily titrated to a target dose of...
nine breaths four times daily. A single breath via the Tyvaso Inhalational System delivers 6 mcg of treprostinil\(^\text{®}\). That being said, limited data exist describing the safety of transition from parenteral to inhaled prostanooids. A multicenter study conducted by de Jesus and colleagues observed a low risk of complications when transitioning eighteen patients from parenteral to inhaled therapy [10]. An additional single center study also reported no complications when transitioning three patients [11].

The aim of this study was to investigate and describe our center's experience with transitioning patients with Group I PAH from parenteral to inhaled prostanooids. We report on the patients' functional and hemodynamic variables pre- and post-transition, and included our detailed protocol used to perform the transitions.

2. Methods

2.1. Patients

University of Florida institutional review board approved the study protocol (UF IRB number 201400983). A single center retrospective observational analysis was conducted in patients over the age of 18 years diagnosed with WHO Group I PAH that were transitioned from intravenous (IV) or subcutaneous prostanooid therapy to inhaled prostanooid therapy treprostinil (Tyvaso\(^\text{®}\); United Therapeutics Corp, Research Triangle Park, NC, USA) at the University of Florida Health Shands Hospital from August 2011 to August 2014. Patient demographics, WHO functional class, clinical data such as the 6 min walk distance (6MWD), and right heart catheterization (RHC) hemodynamic data were collected pre- and at least three months post-transition when available.

2.2. Study design and transition protocol

All transitions were initiated based on patient request. Prior to commencing transition, all patients were made aware of the limited evidence on performing such transitions and the possibility of returning to parenteral prostanooid therapy. All patients enrolled were in addition already receiving dual oral PAH therapies including an endothelial receptor antagonist (ERA) and a phosphodiesterase-5-inhibitor (PDE5i) at the time of transition. The parenteral prostacyclin dose was titrated down in outpatient setting to a goal dose of 20–25 ng/kg/min, or the minimum dose tolerated without experiencing any decline in symptoms or functional class, prior to transition.

All transitions from IV to inhaled therapy were performed in an ICU setting under the care of a multidisciplinary team experienced in the management of patients with PAH. Patients on subcutaneous prostanooids were transitioned in an outpatient setting.

The patients admitted to the ICU for transition, nebulized treprostinil was initiated at a dose of 3 puffs four times a day. The dose of inhaled treprostinil was increased daily to a goal dose of 9 puffs four times a day. During this period the parenteral prostanooid was decreased simultaneously every 6 h (Fig. 1). If side effects were encountered during the transition, the dose of parenteral therapy was increased to the previously tolerated dose and the transition was delayed for 6 h before resuming the titration.

2.3. Statistical methods

Data are presented as a mean ± standard deviation; categorical variables are expressed as a percentage of all patients in the data set. Comparisons of primary and secondary endpoints, before and after transition, were performed using unpaired t-tests for normally distributed data. A p-value < 0.05 was considered statistically significant.

3. Results

A total of 8 patients were transitioned from parenteral prostanooids to inhaled treprostinil, detailed patient demographics and data are presented in Table 1. Prior to initiating the transition, 87.5% (n = 7) of patients were functional class 1 and 2, and 12.5% (n = 1) was functional class 3. Seven patients were on IV epoprostenol while one patient was receiving subcutaneous treprostinil. The average duration of parenteral prostanooid therapy prior to transition was 21.1 ± 12.2 months. Patients with Group I PAH included the following etiologies: idiopathic (n = 5, 62.5%), scleroderma-related (n = 1, 12.5%), secondary to drug abuse (n = 1, 12.5%), or associated with congenital heart disease (n = 1, 12.5%). The most common reason for transition was patient preference related to quality of life (n = 5, 62.5%), followed by line complications (n = 2, 25%), and intolerance to parenteral therapy (n = 1, 12.5%).

RHC hemodynamic parameters, functional class, and 6MWD were analyzed for all patients prior to and after transition when available (Table 2). RHC data was available in 4 patients at least three months after transition. The mean parenteral prostacyclin dose prior to initiating the transition was 22.6 ± 7.7 ng/kg/min. The average ICU and hospital length of stay was 4.1 ± 0.7 days for those transitioned as an inpatient. Only one adverse side effect was observed in one patient during the transition (n = 1, 12.5%), a coughing episode, which required the slowing down of the transition by 6 h.

The average follow up was 19.6 ± 11.1 months, with no difference in the functional class status or the 6MWD when compared to the pre-transition period (406.3 ± 100.8 m versus 418.5 ± 120.9 m, p = 0.62). Follow-up RHC hemodynamics after transition were available for four patients at least three months after the transition period. Only one patient failed inhaled therapy necessitating transition back to intravenous epoprostenol.

4. Discussion

Limited data exists supporting the transition of patients from parenteral epoprostenol therapy to parenteral treprostinil [12–15], inhaled iloprost [16,17], and inhaled treprostinil [10,11]. Currently, there is an ongoing prospective trial evaluating the transition of patients from parenteral to inhaled prostacyclins (NCT01268553).

The non-invasive and convenient method of administering...
Table 1
Patient characteristics.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age, y</th>
<th>Sex</th>
<th>PAH</th>
<th>Parenteral therapy</th>
<th>Parenteral duration in months</th>
<th>Other PAH drugs</th>
<th>Reason for transition</th>
<th>Complications</th>
<th>LOS, days</th>
<th>Follow up in months</th>
<th>Failed therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66</td>
<td>M</td>
<td>IPAH</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8</td>
<td>Bosentan, sildenafil</td>
<td>Line complications</td>
<td>—</td>
<td>3</td>
<td>37</td>
<td>N</td>
</tr>
<tr>
<td>2</td>
<td>57</td>
<td>F</td>
<td>IPAH</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5</td>
<td>Ambrisentan, tadalafil</td>
<td>Preference</td>
<td>—</td>
<td>4</td>
<td>33</td>
<td>N</td>
</tr>
<tr>
<td>3</td>
<td>79</td>
<td>F</td>
<td>IPAH</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18</td>
<td>Ambrisentan, tadalafil</td>
<td>Intolerance</td>
<td>Coughing</td>
<td>5</td>
<td>24</td>
<td>N</td>
</tr>
<tr>
<td>4</td>
<td>56</td>
<td>M</td>
<td>SCL</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>23</td>
<td>Bosentan, sildenafil</td>
<td>Preference</td>
<td>—</td>
<td>4</td>
<td>20</td>
<td>Y</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>F</td>
<td>IPAH</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>39</td>
<td>Ambrisentan, sildenafil</td>
<td>Intolerance</td>
<td>—</td>
<td>4</td>
<td>16</td>
<td>N</td>
</tr>
<tr>
<td>6</td>
<td>30</td>
<td>F</td>
<td>Drug</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13</td>
<td>Ambrisentan, tadalafil</td>
<td>Preference</td>
<td>—</td>
<td>4</td>
<td>11</td>
<td>N</td>
</tr>
<tr>
<td>7</td>
<td>61</td>
<td>F</td>
<td>IPAH</td>
<td>Epoprostenol&lt;sup&gt;a&lt;/sup&gt;</td>
<td>31</td>
<td>Bosentan, tadalafil</td>
<td>Preference</td>
<td>—</td>
<td>5</td>
<td>7</td>
<td>N</td>
</tr>
<tr>
<td>8</td>
<td>36</td>
<td>F</td>
<td>CHD</td>
<td>Treprostinil&lt;sup&gt;b&lt;/sup&gt;</td>
<td>32</td>
<td>Ambrisentan, tadalafil</td>
<td>Preference</td>
<td>NA</td>
<td>9</td>
<td>9</td>
<td>N</td>
</tr>
</tbody>
</table>

CHD- congenital heart disease; IPAH- idiopathic pulmonary arterial hypertension; LOS- length of stay; M-male; F- female; NA- not applicable; PAH- pulmonary arterial hypertension; SCL- scleroderma; Y- years.

<sup>a</sup> Intravenous.

<sup>b</sup> Subcutaneous.

Table 2
Cardiopulmonary function pre- and post-transition.

<table>
<thead>
<tr>
<th>Pre transition</th>
<th>Post transition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject</td>
<td>RA</td>
</tr>
<tr>
<td>-----------</td>
<td>-----</td>
</tr>
<tr>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>8</td>
<td>12</td>
</tr>
</tbody>
</table>

6MWD = 6 min walk distance; CO = cardiac output via thermodilution; FC = WHO functional class; mPAP = mean pulmonary arterial pressure; PAOP = pulmonary artery occlusion pressure; PVR = pulmonary vascular resistance; RA = right atrial pressure.

<sup>a</sup> Measurement in mm Hg.

<sup>b</sup> Measurement in L/min.

<sup>c</sup> Measurement in wood units.

<sup>d</sup> Measurement in meters.

---

Fig. 2. Example intravenous epoprostenol to inhaled treprostinil transition.
inhaled prostanooids makes it an attractive alternative for safer drug delivery in selected patients with PAH who want to avoid the complications associated with IV and subcutaneous therapy [9,10,18,19]. This is reflected in our study, as the reason for transition to nebulized therapy was ultimately patient preference. Unfortunately, sparse data is available describing the process of conversion to inhaled therapy among different centers [10,11], and not all patients are candidates to undergo such transition.

Patients with advanced severe PAH associated with right-sided heart failure, and those on high parenteral prostacyclin doses that cannot be decreased to a parenteral dose of 20–25 ng/kg/min, should not be transitioned. One patient with scleroderma (subject 4) tolerated inhaled therapy for 20 months before being transitioned back to parenteral therapy due to the progressive nature of his underlying disease.

The transition process was explained in detail to all patients. We chose a 48–72 h frame for transition to allow time to educate patients on the use of their inhaled therapy during the transition and to monitor them closely. All patients showed quick understanding in the use of their new inhaled treatment within the first 24 h and we had only one complication, severe coughing episode in one patient, requiring slowing down the transition process by six hours. Overall, transitioning from parenteral prostacyclin therapy to inhaled treprostinil appears to be safe and well tolerated when using our protocol. An example of one patient’s transition can be found in Fig. 2.

We appreciate the limitations of our study, the small number of patients in a single center does underpower our statistical analysis, and the follow-up period was widely variable. As such, these results may not be extrapolated accurately to a larger population but our aim was to describe the protocol we implemented to serve as a guide for physicians caring for patients with pulmonary arterial hypertension. That said, we still advise caution when selecting patients for transition, as patients with progressive disease such as portopulmonary hypertension and scleroderma may not be ideal candidates.

Of note, all of the transitioned patients in our study were already receiving triple therapy for their pulmonary arterial hypertension prior to transition. The observed clinical stability after transition may not be due to inhaled therapy, but due to the combination of PAH therapies targeting different pathways. We believe that select patients that respond favorably to combination treatment with oral and parenteral therapy can be safely transition from parenteral to inhaled prostacyclin therapy.

In conclusion, transitioning patients from parenteral to inhaled prostacyclin therapy can be safely accomplished in specialized centers over a period of 48–72 h. Patient preference was overwhelming the most prevalent reason for transition. We propose an algorithm that has been proven to be safe when transitioning patients from parenteral to inhaled prostacyclin therapy at our institution.

Disclosure

All authors have no conflicts of interest to disclose.

Acknowledgments

The authors contributed significantly to the submitted work. Ali Ataya, corresponding author, contributed to the conception and design of the study, the analysis and interpretation of the data and, revision of the manuscript. Angelina Somoracki contributed to the conception and design of the study, the analysis and interpretation of the data, and revision of the manuscript. Jessica Cope contributed to the conception and design of the study, the analysis and interpretation of the data, and revision of the manuscript. Hassan Alnauimat is the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to publication. All authors gave their approval to the final draft of the manuscript.

References


Abbreviation list

6MWD: 6 min walk distance
ERA: endothelial receptor antagonist

ICU: intensive care unit
IV: intravenous
PAH: pulmonary arterial hypertension
PDE5i: phosphodiesterase-5-inhibitor
RHC: right heart catheterization
WHO: World Health Organization